PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC) Median Overall Survival of 17.3 months in ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the ...

June 4, 2025 in Chicago, IL. Zymeworks will present a TiP poster at the ESMO Gynaecological Cancers Congress, which is taking place June 19-21, 2025 in Vienna, Austria. Title Authors Presentation ...

Title: ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33, Potently Inhibits Key Mediators of Airway Inflammation ...